REDEMPLO gains NHS backing for genetically confirmed FCS in England and Wales, following strong triglyceride reductions in the PALISADE trial.
Avanzanite appoints Sarah O'Connell to expand UK rare disease operations. The move strengthens its European commercialisation and patient access strategy.
Find out how Epitopea’s CryptiVax-1001 trial could reshape RNA cancer vaccines and ovarian cancer treatment strategies.
Savara's molgramostim BLA faces no FDA adcom. Analysis of what the August 2026 PDUFA date means for autoimmune PAP treatment access. Read more.